T1	Concept 87 97	SARS-CoV-2
T2	Concept 102 112	Human SARS
T3	Concept 135 142	Bat CoV
T4	Concept 42 58	disorder segment
T5	Concept 37 41	long
R1	has-property Arg1:T4 Arg2:T5	
T6	Concept 0 4	Nsp8
T7	Concept 5 13	proteins
R2	is-a Arg1:T6 Arg2:T7	
T8	Action 17 26	predicted
R3	subject Arg1:T8 Arg2:T6	
R4	target Arg1:T8 Arg2:T4	
T9	Concept 64 78	44-84 residues
R5	in-context Arg1:T4 Arg2:T9	
R6	in-context Arg1:T9 Arg2:T1	
R7	in-context Arg1:T9 Arg2:T2	
T10	Concept 117 131	48-84 residues
R8	in-context Arg1:T4 Arg2:T10	
R9	in-context Arg1:T10 Arg2:T3	
T12	Concept 205 215	SARS-COV-2
T13	Concept 216 226	Human SARS
T14	Concept 232 239	Bat CoV
T15	Concept 253 262	mean PPID
T16	Concept 656 676	SARS-COV-2 infection
T17	Concept 716 728	liver injury
A1	Uncertain T16
R10	causes Arg1:T16 Arg2:T17	
T18	Concept 769 780	respiratory
T19	Concept 784 797	blood samples
T20	Concept 810 816	RT-PCR
T21	Concept 922 932	SARS-CoV-2
T22	Concept 860 873	blood samples
T23	Concept 179 187	disorder
T24	Concept 169 178	intrinsic
R11	has-property Arg1:T23 Arg2:T24	
T25	Concept 551 561	SARS-CoV-2
T26	Concept 742 752	SARS-CoV-2
T27	Concept 753 765	nucleic acid
R16	has-part Arg1:T26 Arg2:T27	
R17	in-place Arg1:T27 Arg2:T18	
R18	in-place Arg1:T27 Arg2:T19	
T28	Concept 729 737	Positive
R19	has-property Arg1:T27 Arg2:T28	
T29	Action 798 806	detected
R20	subject Arg1:T29 Arg2:T27	
R21	target Arg1:T29 Arg2:T20	
T30	Concept 845 856	respiratory
T31	Concept 886 894	homology
A2	Emphasized T31
T32	Concept 818 832	Virus sequence
T33	Action 874 880	shares
R22	subject Arg1:T33 Arg2:T32	
R23	target Arg1:T33 Arg2:T31	
R24	in-context Arg1:T31 Arg2:T21	
R25	in-place Arg1:T32 Arg2:T30	
R26	in-place Arg1:T32 Arg2:T22	
T35	Concept 525 542	antiviral effects
A3	Uncertain T35
T34	Concept 392 412	therapeutic shortcut
R27	in-context Arg1:T35 Arg2:T25	
T36	Concept 608 620	clinical use
T37	Concept 633 648	clinical trials
T38	Action 595 603	approved
R28	target Arg1:T38 Arg2:T36	
R29	target Arg1:T38 Arg2:T37	
T39	Concept 574 579	drugs
R30	subject Arg1:T38 Arg2:T39	
R31	has-property Arg1:T39 Arg2:T35	
T40	Concept 448 456	strategy
T41	Concept 434 447	repositioning
T42	Concept 429 433	drug
R32	is-a Arg1:T41 Arg2:T40	
R33	in-context Arg1:T41 Arg2:T42	
T43	Concept 191 192;193 201	M proteins
T44	Concept 191 192;193 201	M proteins
R13	in-place Arg1:T44 Arg2:T12	
R15	in-place Arg1:T43 Arg2:T14	
R34	in-place Arg1:T23 Arg2:T44	
R35	in-context Arg1:T23 Arg2:T43	
T11	Concept 191 192;193 201	M proteins
R12	in-place Arg1:T23 Arg2:T11	
R14	in-place Arg1:T11 Arg2:T13	
T45	Action 325 336	development
T46	Concept 346 350	drug
T47	Concept 342 345	new
R36	has-property Arg1:T46 Arg2:T47	
R37	target Arg1:T45 Arg2:T46	
T48	Concept 367 372	years
A4	Uncertain T48
R38	in-time Arg1:T45 Arg2:T48	
T49	Concept 266 271	2.70%
T50	Concept 273 278	1.36%
T51	Concept 284 289	1.36%
R39	in-context Arg1:T23 Arg2:T15	
